Related Experiment Video
Updated: Jul 6, 2026
08:50
Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
Published on: January 9, 2026
[Therapeutic consequences of thrombophilic testing]
J Constans1, C Boulon, A Solanilla
1Service de médecine vasculaire et médecine interne, hôpital Saint-André, 1, rue Jean-Burguet, 33075 Bordeaux, France. joel.constans@chu-bordeaux.fr
La Revue De Medecine Interne
|April 9, 2008
Summary
Thrombophilia testing offers limited impact on treatment decisions for most patients. Antiphospholipid antibodies are crucial to identify due to their known effect on recurrence risk.
Area of Science:
- Hematology
- Genetics
- Clinical Medicine
Context:
- Congenital thrombophilic testing indications have expanded with the discovery of common genetic abnormalities.
- Thrombophilia testing is often considered after venous thromboembolism events.
- The clinical utility of thrombophilia testing in specific scenarios remains under evaluation.
Purpose:
- To review current data on the consequences of thrombophilia testing.
- To critically evaluate the indications for thrombophilia testing.
- To inform clinical decision-making regarding thrombophilia diagnosis and management.
Summary:
- Most congenital thrombophilias do not significantly increase recurrence risk after venous thromboembolism.
- Factor V Leiden mutation confers a moderate increase in recurrence risk; Factor II G20210A mutation does not.
- Decreased antithrombin levels may be associated with increased recurrence risk, but evidence is inconclusive.
Impact:
- Identification of specific thrombophilias (e.g., antithrombin deficiency, homozygous mutations) can influence therapeutic decisions.
- Testing for antiphospholipid antibodies is essential due to their established impact on recurrence.
- Routine thrombophilia work-up is generally not recommended after superficial or distal venous thrombosis, except for antiphospholipid antibodies.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:13Therapeutic Index
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.